Skip to main content
NCBI home page
Data in Brief logoLink to Data in Brief
. 2018 Oct 12;21:742–745. doi: 10.1016/j.dib.2018.10.030

Spherical particles derived from TMV virions enhance the protective properties of the rabies vaccine

NA Nikitin a,⁎, IN Matveeva b, EA Trifonova a, NM Puhova b, A Ya Samuylenko b, SA Gryn b, JG Atabekov a, OV Karpova a
PMCID: PMC6214837  PMID: 30406165

Abstract

In this study the ability of spherical particles (SPs) obtained from the tobacco mosaic virus (TMV) virions to enhance the immunogenic potential of the vaccine was evaluated. TMV SPs were shown to increase the protective properties of the widely used effective Russian adjuvant-free rabies vaccine, composed of killed rabies virions. The results of the NIH potency test showed enhancement of protectivity, that is comparable with the effect of the incomplete Freund׳s adjuvant on the same vaccine.

Keywords: Rabies vaccine, Plant virus, Spherical particles, Adjuvant

Specifications table

Subject area Biology
More specific subject area Vaccines, Plant Virology
Type of data Table
How data was acquired NIH potency test
Data format Analyzed
Experimental factors Spherical particles production by thermal transition of TMV. Virus inactivation test
Experimental features Enhancement of protective potential of commercial vaccine by new candidate adjuvant – TMV SPs
Data source location Department of Virology, Lomonosov Moscow State University,1–12 Leninskie gory, Moscow 119234, Russia
Data accessibility Data are provided with this article
Open in a new tab

Value of the data

  • ●

    Here we shown the ability of a potent immunity enhancer - spherical particles (SPs) derived from tobacco mosaic virus (TMV) virions by the thermal remodelling - to increase the protectivity of the effective killed rabies vaccine Rabikan™. Rabikan (composed of the inactivated rabies virions) is the most widely used adjuvant-free veterinary rabies vaccine in Russian Federation, that for a long time demonstrate high efficacy.

  • ●

    Our data demonstrate that TMV SPs have nearly the same immune stimulating potency as Freund׳s incomplete adjuvant. However unlike Freund׳s incomplete adjuvant TMV SPs do not cause local inflammatory reactions on laboratory animal and can be easily biodegraded [1]. As well TMV SPs have low cost of production and high biosafety due to the absence of common pathogens between mammals and plants [2].

  • ●

    The results clearly point out, that TMV SPs should be considered as a promising safe candidate for a next generation adjuvant.

1. Data

This work is an essential step for evaluation of TMV SPs as effective safe adjuvant for vaccines development. Here the data of TMV SPs enhancement of widely used adjuvant-free rabies vaccine protectivity were shown by NIH potency test.

2. Experimental design, materials and methods

2.1. SP production

The detailed protocol for extraction and purification of TMV from the infected Nicotiana tabacum L. cv. Samsun leaves was described previously [3]. SP samples were prepared from TMV according to [4]. The morphology and size distribution of the obtained TMV spherical particles were subsequently analyzed by transmission electron microscopy and nanoparticle tracking analysis according to [5]. TMV SPs samples were 100 µg per dose of vaccine with average particle size 285 ± 4 nm.

2.2. Ethics statement

All experimental procedures with animals were performed according to European Communities guidelines [6], guide for the care and use of laboratory animals [7] and Ethical Code of the Russian Veterinarian recommended on the XIII Moscow International Veterinary Congress of Russian Small Animal Veterinary Association on April, 2005 (Moscow, Russia).

2.3. Virus inactivation test

The lyophilized vaccine Rabikan™ (Ser. No 132, FSE "SHCHELKOVO Biokombinat", Russia) was used as a basic rabies vaccine for comparing of the adjuvant potential. In order to confirm virus inactivation, 10 mice were injected intracerebrally with 0.03 ml of the reconstituted vaccine [8]. Animals were observed daily within the 14-days interval for detection of obvious rabies symptoms.

2.4. NIH potency test

The reference vaccine (national standard antirabic vaccine СТО-00494189-0042-2010, 1.8 IU/ml) and the test samples of vaccine adjusted with different adjuvants were serially diluted with Hank׳s medium up to 1:5, 1:25, 1:125, 1:625 and 1:3125 (see Table 1). According to the standard protocol [8], [9], each dilution was injected intraperitoneally into 16 BALB/c mice twice with a 7 day gap. Mice were distributed equally by sex. To evaluate the titre of the challenge virus standard (CVS-11), 3 groups of 10 animals were injected intracerebrally with 0.03 ml of the CVS, diluted to 1:10, 1:100, 1:1000. Mice were challenged intracerebrally with CVS dose of 5–50 LD50 in 0.03 ml, 7 days after the last immunization and observed for 14 days. Deaths after the day 5 post lethal challenge were counted, as well as mice alive though symptomatic on day 14. According to NIH protocol, mice dead before 5 days following challenge were recorded as non-specific death. The number of registered non specific death was removed from the total number during effective dose (ED50) calculation. Deaths during experimental period were recorded as specific and non-specific using fluorescent antibody test as confirmatory using brain samples. The relative vaccine potency was calculated by comparison of ED50 with the same value, calculated for the reference vaccine. ED50 value was calculated according to the Spearman-Kärber formula. To reduce the suffering and total number of sacrificed laboratory animals, all vaccine batches with different adjuvants were tested simultaneously with a single batch of the reference vaccine. Animals were euthanized as soon as severe rabies symptoms being noticed.

Table 1.

Results of the NIH potency test.

Vaccine/adjuvant Vaccine Volume (ml/injection) Vaccine dilutions N. mice N. of mice 14 days after the control intracerebral infection with the reference strain CVS-11 (cerebral strain - challenge virus standard)
 ED50 Relative Potency (IU/ml)
Survived Dead
National Reference Vaccine 0.5 1:5 16 16 0 2,75 1,8
1:25 16 14 2
1:125 16 11 5
1:625 16 9 7
1:3125 16 5 11
RabikanТМ+PBS (Control) 0.5 1:5 16 16 0 2,66 1,47
1:25 16 13 3
1:125 16 11 5
1:625 16 9 7
1:3125 16 4 12
RabikanТМ+TМV SPs -100 μg /dose 0.5 1:5 16 16 0 2,8 1,99
1:25 16 13 3
1:125 16 12 4
1:625 16 10 6
1:3125 16 5 11
RabikanТМ+Incomplete Freund׳s adjuvant 0.1a 1:5 16 16 0 2,79 1,98
1:25 16 13 3
1:125 16 12 4
1:625 16b 9 6
1:3125 16b 5 10
Open in a new tab
a

The final injected volume was 0.2 ml, as 0.1 ml of Freund׳s incomplete adjuvant (Sigma) was added to each vaccine dilution.

b

One non-specific death.

Acknowledgements

This work was supported by the Russian Science Foundation (Grant no. 18-14-00044).

Footnotes

Transparency document

Transparency document associated with this article can be found in the online version at https://doi.org/10.1016/j.dib.2018.10.030.

Transparency document. Supplementary material

Transparency document

mmc1.zip (8.9MB, zip)

.

References

  • 1.Nikitin N.A., Malinin A.S., Rakhnyanskaya A.A., Trifonova E.A., Karpova O.V., Yaroslavov A.A., Atabekov J.G. Use of a polycation spacer for noncovalent immobilization of albumin on the thermally modified virus particles. Polym. Sci. Ser. 2011;53:1026–1031. [Google Scholar]
  • 2.Nikitin N.A., Trifonova E.A., Karpova O.V., Atabekov J.G. Biosafety of plant viruses for human and animals. Mosc. Univ. Biol. Sci. Bull. 2016;71(3):128–134. [Google Scholar]
  • 3.Trifonova E.A., Nikitin N.A., Kirpichnikov M.P., Karpova O.V., Atabekov J.G. Obtaining and characterization of spherical particles—new biogenic platforms. Mosc. Univ. Biol. Sci. Bull. 2015;70(4):194–197. [Google Scholar]
  • 4.Trifonova E.A., Zenin V.A., Nikitin N.A., Yurkova M.S., Ryabchevskaya E.M., Putlyaev E.V., Donchenko E.K., Kondakova O.A., Fedorov A.N., Atabekov J.G., Karpova O.V. Study of rubella candidate vaccine based on a structurally modified plant virus. Antivir. Res. 2017;144:27–33. doi: 10.1016/j.antiviral.2017.05.006. [DOI] [PubMed] [Google Scholar]
  • 5.Nikitin N., Trifonova E., Evtushenko E., Kirpichnikov M., Atabekov J., Karpova O. Comparative study of non-enveloped Icosahedral viruses size. PLoS One. 2015;10(11):e0142415. doi: 10.1371/journal.pone.0142415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes, OJ L 276, 2010, pp. 33–79.
  • 7.Guide for the Care and Use of Laboratory Animals (eighth edition). The National Academy Press, Washington, D.C., 2011.
  • 8.Szaret P. General consideration in testing the safety and potency of rabies vaccine. In: Meslin F.X., Kaplan M.M., Koprowski H., editors. Laboratory Techniques in Rabies. 4th ed. World Health Organization; Geneva: 1996. pp. 355–359. [Google Scholar]
  • 9.Wilbur L.A., Aubert M.F.A. The NIH test for potency. In: Meslin F.X., Kaplan M.M., Koprowski H., editors. Laboratory Techniques in Rabies. 4th ed. World Health Organization; Geneva: 1996. pp. 360–368. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Transparency document

mmc1.zip (8.9MB, zip)

Articles from Data in Brief are provided here courtesy of Elsevier

RESOURCES